Inscrição na biblioteca: Guest
Critical Reviews™ in Oncogenesis

Publicou 4 edições por ano

ISSN Imprimir: 0893-9675

ISSN On-line: 2162-6448

SJR: 0.395 SNIP: 0.322 CiteScore™:: 2.5 H-Index: 54

Indexed in

Posttranslational Regulation of p53 Tumor Suppressor Protein Function

Volume 5, Edição 1, 1994, pp. 23-58
DOI: 10.1615/CritRevOncog.v5.i1.20
Get accessGet access

RESUMO

Alteration of the p53 gene by deletion and mutation is the most common denominator yet identified among human cancers (Hollstein et al., 1991; Caron de Fromental and Soussi, 1992). The involvement of the p53 gene in such a broad scope of human cancers warrants further investigation into its mechanism of action in regulating cell growth. The wild-type p53 protein restricts cell growth in the G, phase of the cell cycle by regulating the transcription of genes and possibly, by influencing DNA replication. Elucidating the cell growth restriction of p53 will require identification and characterization of the genes whose expression is regulated by p53 and the proteins that interact with p53 to regulate its DNA-binding and transactivation functions. A model for the regulation of p53 biochemical function is proposed that extends further and builds on the conformational hypothesis for regulation of p53 function hypothesized by Milner (1991) and Ullrich et al. (1992a). The conformational hypothesis of regulation of p53 function states that the conformation of p53 determines whether it expresses growth-suppressing or growth-promoting biological activity. Mutations observed in human cancer lock p53 in a growth-promoting conformation. We expand the conformational hypothesis in a regulatory model that includes binding proteins, kinases/phosphatases, redox modifier proteins, and homo/hetero-oligomerization, which modulate the tertiary structure of the protein. Different conformational modes of p53 interact differently with initiation complexes at gene promoters and at origins of DNA replication. Each form of p53, depending on its interaction with proteins and gene transcription-initiation complexes, will mediate distinct biological effects on cells ranging from growth suppression to growth promotion. Furthermore, depending on its conformational state, p53 can repress or activate other transcription factors thus indirectly affecting gene regulation. We propose that each cell and tissue type expresses unique quantities and types of p53-binding proteins and modifying enzymes that regulate the interaction of p53 with promoters of genes necessary for control of growth of a specific cell or tissue. It is anticipated that defects in the expression of p53 regulatory proteins are involved in a portion of those tumors expressing normal p53. Defects in the p53 biochemical pathway may thus be even more prevalent in human cancers than is now realized.

CITADO POR
  1. HAMMITT KATHERINE MORLAND, ALEXANDER ELAINE L., Lymphoma and Autoimmune Disease, in The Autoimmune Diseases, 2006. Crossref

  2. Lin Kwang-Huei, Shieh Hsing-Ying, Chen Shen-Liang, Hsu Hai-Chu, Expression of mutant thyroid hormone nuclear receptors in human hepatocellular carcinoma cells, Molecular Carcinogenesis, 26, 1, 1999. Crossref

  3. Whitfield James F., Bird Ranjana P., Chakravarthy Balu R., Isaacs Richard J., Morley Paul, Calcium—cell cycle regulator, differetiator, killer, chemopreventor, and maybe, tumor promoter, Journal of Cellular Biochemistry, 59, S22, 1995. Crossref

  4. Zacchetti A., van Garderen E., Rutteman G. R., Immunohistochemical evaluation of p53 expression with different antibodies in malignant canine tumours with or without p53 gene mutation, Veterinary and Comparative Oncology, 5, 2, 2007. Crossref

  5. Gruss H. -J., Molecular, structural, and biological characteristics of the tumor necrosis factor ligand superfamily, International Journal of Clinical & Laboratory Research, 26, 3, 1996. Crossref

  6. Ragnarsson-Olding Boel, Platz Anton, Olding Lars, Ringborg Ulrik, p53 protein expression and TP53 mutations in malignant melanomas of sun-sheltered mucosal membranes versus chronically sun-exposed skin, Melanoma Research, 14, 5, 2004. Crossref

  7. BARRERA-HERNANDEZ GONZALO, ZHAN QIMIN, WONG ROSEMARY, CHENG SHEUE-YANN, Thyroid Hormone Receptor Is a Negative Regulator in p53-Mediated Signaling Pathways, DNA and Cell Biology, 17, 9, 1998. Crossref

  8. Milczarek Gavin J., Martinez Jesse, Bowden G.Tim, p53 phosphorylation: Biochemical and functional consequences, Life Sciences, 60, 1, 1996. Crossref

  9. Bristow Robert G., Benchimol Samuel, Hill Richard P., The p53 gene as a modifier of intrinsic radiosensitivity: implications for radiotherapy, Radiotherapy and Oncology, 40, 3, 1996. Crossref

  10. Talve L., Kainu. J., Collan Y., Ekfors T., Immunohistochemical Expression of p53 Protein, Mitotic Index and Nuclear Morphometry in Primary Malignant Melanoma of the Skin, Pathology - Research and Practice, 192, 8, 1996. Crossref

  11. Sun Yi, Oberley Larry W., Redox regulation of transcriptional activators, Free Radical Biology and Medicine, 21, 3, 1996. Crossref

  12. Tsou Shang-Hsun, Chen Tzer-Ming, Hsiao Hui-Ting, Chen Yen-Hui, Lee Jung Weon, A Critical Dose of Doxorubicin Is Required to Alter the Gene Expression Profiles in MCF-7 Cells Acquiring Multidrug Resistance, PLOS ONE, 10, 1, 2015. Crossref

  13. Nicolatou-Galitis Ourania, Papadaki Theodora, Moshovi Maria, Kamma Joanna J., Vliet-Constantinidou Cathrine Van, Tsoumakas Constantine, Kattamis Antonis, Tzortzatou-Stathopoulou Fotini, Gingival Overgrowth as the Initial Paraneoplastic Manifestation of Hodgkin's Lymphoma in a Child. A Case Report, Journal of Periodontology, 72, 1, 2001. Crossref

  14. Koppaka Vindhya, Chen Ying, Mehta Gaurav, Orlicky David J., Thompson David C., Jester James V., Vasiliou Vasilis, Ljubimov Alexander V., ALDH3A1 Plays a Functional Role in Maintenance of Corneal Epithelial Homeostasis, PLOS ONE, 11, 1, 2016. Crossref

  15. Trouba Kevin J., Hamadeh Hisham K., Amin Rupesh P., Germolec Dori R., Oxidative Stress and Its Role in Skin Disease, Antioxidants & Redox Signaling, 4, 4, 2002. Crossref

  16. De Beeck Anne Op, Caillet-Fauquet Perrine, Viruses and the cell cycle, in Progress in Cell Cycle Research, 1997. Crossref

  17. Ferreira C.G., Tolis C., Giaccone G., p53 and chemosensitivity, Annals of Oncology, 10, 9, 1999. Crossref

  18. Miller S D, Moses K, Jayaraman L, Prives C, Complex formation between p53 and replication protein A inhibits the sequence-specific DNA binding of p53 and is regulated by single-stranded DNA, Molecular and Cellular Biology, 17, 4, 1997. Crossref

  19. Ko L J, Prives C, p53: puzzle and paradigm., Genes & Development, 10, 9, 1996. Crossref

  20. Sidransky, M.D David, Hollstein, Ph.D Monica, CLINICAL IMPLICATIONS OF THE p53 GENE, Annual Review of Medicine, 47, 1, 1996. Crossref

  21. Bhat Manoj Kumar, Yu Chia-lin, Yap Nida, Zhan Qimin, Hayashi Yoshitaka, Seth Prem, Cheng Sheue-yann, Tumor Suppressor p53 Is a Negative Regulator in Thyroid Hormone Receptor Signaling Pathways, Journal of Biological Chemistry, 272, 46, 1997. Crossref

  22. Yuan Ang, Yu Chong-Jen, Luh Kwen-Tay, Kuo Sow-Hsong, Lee Yung-Chie, Yang Pan-Chyr, Aberrant p53 Expression Correlates With Expression of Vascular Endothelial Growth Factor mRNA and Interleukin-8 mRNA and Neoangiogenesis in Non–Small-Cell Lung Cancer, Journal of Clinical Oncology, 20, 4, 2002. Crossref

Portal Digital Begell Biblioteca digital da Begell eBooks Diários Referências e Anais Coleções de pesquisa Políticas de preços e assinaturas Begell House Contato Language English 中文 Русский Português German French Spain